Background: The best therapeutic measures in patients with eclampsia are termination of pregnancy, administration of anticonvulsant drugs, control of blood pressure with antihypertensive drugs, and critical care to improve outcome. This study aimed to analyze the pharmacological management of arterial hypertension and clinical outcome of a retrospective cohort of patients with eclampsia. Methods: This is a retrospective cohort of 37 patients with eclampsia from the intensive care unit (ICU). The files were consulted to know their general data, the characteristics of the seizures and blood pressure. Changes in blood pressure at admission vs. discharge were compared, as well as antihypertensive management and outcome. Descriptive statistics and the Student's t-test with the SPSS version 20 program were used. P=0.05 was significant. Results: Mean age 25.86±7.82 years and gestation 33.48±3.97 weeks. Patients with pregnancy 56.76% and puerperium 43.24%. Anticonvulsant drugs was administered in 100% (magnesium sulfate, sodium phenytoin, diazepam). Systolic blood pressure: admission vs discharge 143.08±22.10 vs 125.7±11.26 mmHg (P=0.06) and diastolic blood pressure: admission vs discharge 88.69±14.15 vs 76.6±9.56 mmHg (P=0.76). It was found that 91.89% received antihypertensive drugs and 8.11% none. Indeed, a group of patients with severe preeclampsia convulsed in the ICU 21.63% (n=8/37) when they were already receiving anticonvulsant drugs. In them, pre-seizure blood pressure increased compared to admission pressure (systolic 13.53%, P=0.05, diastolic 22.46%, P=0.05), one patient did not have antihypertensive management and seven patients received only oral antihypertensive drugs. ICU stay was similar to that of the group (P=0.20). Mortality was 0%. Conclusion: The evolution of the patients was not satisfactory, but without maternal deaths. Eight new cases of eclampsia occurred in the ICU with uncontrolled hypertension, probably due to insufficient pharmacological management. The data suggest not discontinuing antihypertensive agents despite blood pressure remaining controlled. Deviations from the handling guidelines should be avoided.
Background: The management of postpartum hypertension is a priority in severe preeclampsia (SP) to reduce short and long term complications. This study aimed to analyze the results of the management of postpartum arterial hypertension in patients with SP of a high specialty hospital of Mexico City. Methods: An observational, longitudinal, retrospective and analytical study was carried out in a series of 91 pregnant women with SP admitted to the Intensive Care Unit (ICU) from May 1 to September 30, 2019 with termination of pregnancy and postpartum stay in the same hospital. Systolic blood pressure (SBP), diastolic blood pressure (DBP) and antihypertensive management were compared on admission (prepartum, baseline measurement) and on days 1, 3 and 7 postpartum. Statistical analysis: descriptive statistics, Student t test and two-way ANOVA test with the statistical program SPSS version 20. Results: Age 30.91±6.69 years, parity 2 and pregnancy of 32.48±4.21 weeks. SBP gradually decreased, at the end of the study the changes had statistical significance (baseline measurement 163.08±16.52, vs day 1 133.78±22.11 P=.150, vs day 3 131.56±21.07 P=0.051, vs day 7 125.02±17.79 P=0.007). DBP also decreased, but at the end of the study the changes were not significant (baseline measurement 100.29±13.06, vs day 1 82.02±13.88 P=.61, vs day 3 80.87±11.98 P=.11, day 7 78.02±10.78 P=.14. At the beginning, the combination of two to five oral drugs was necessary, but in the end the number of drugs was reduced. Blood pressure was controlled (<140/90 mmHg) in 87.92% (n=80), and 12.08% (n=11) continued with uncontrolled hypertension (≥140/90 mmHg). Stay in the ICU was 2.33±2.12 days, hospital stay 7.23±3.69 days and mortality 0%. Conclusion: SBP was significantly improved, but not DBP. Polypharmacy was necessary in most cases. A significant number of patients did not have adequate blood pressure control.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.